BioMarin Pharmaceutical Inc. announced last November that longtime CEO Jean-Jacques Bienaimé would retire, with Genentech, Inc. CEO Alexander Hardy replacing him, and changes to its C-suite have continued since then. The company said on 21 August that Amgen, Inc. vice president of medical affairs, rare diseases Greg Friberg will become EVP and chief research and development officer, effective 30 September, and Hardy’s former colleague, retired Roche Pharma Partnering head James Sabry, has been named EVP and chief business officer, effective 7 October.
BioMarin Recruits Amgen R&D’s Friberg, Roche Dealmaker Sabry To Leadership Team
Third And Fourth C-Suite Changes Since November
The company, in its new profitable era, is bringing in new leadership, with Amgen VP of medical affairs for rare diseases Greg Friberg and recently retired Roche Partnering head James Sabry.
More from Leadership
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Scrip
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.